ALLHAT: Is the final answer in?

Heart Disease

Volumn 5, Issue 3, 2003, Pages 171-175

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; PRAVASTATIN; RAMIPRIL; RESERPINE; THIAZIDE DIURETIC AGENT;

CLINICAL RESEARCH; CLINICAL TRIAL; DIABETES MELLITUS; DRUG RESEARCH; EDITORIAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; NEGRO;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHLORTHALIDONE; DIABETES COMPLICATIONS; DIURETICS; HUMANS; HYPERTENSION; KIDNEY; RANDOMIZED CONTROLLED TRIALS;

EID: 0037937589     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000074435.50685.4a     Document Type: Editorial

References (18)

1. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1996;9:342-360.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor therapy or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
3. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic patients randomized to pravastatin versus usual care. JAMA. 2002;288:2998-3007.
4. Grimm RH Jr, Margolis KL, Papademetriou V, et al. Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2001;37:19-27.
5. Barzilay JI, Jones CL, Davis BR, et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001;24:654-658.
6. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens. 1995;9:342-360.
7. Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A.
8. Sequeira RP, Jassim KA, Damanhori AH, et al. Prescribing pattern of antihypertensive drugs by family physicians and general practitioners in the primary care setting in Bahrain. J Eval Clin Pract. 2002;8:407-414.
9. Weir MR, Weber MA, Punzi HA, et al. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Human Hypertens. 1992;6:133-138.
10. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol. 1985;7(Suppl):52-55.
11. Weir MR, Gray JM, Paster R, et al. Differing mechanisms of action of angiotensin converting enzyme inhibition in black and white hypertensive patients. Hypertension. 1995;25:124-130.
12. Wing LM, Chalmers JP, West MJ, et al. Enalapril and atenolol in essential hypertension: attenuation of hypotensive effects in combination. Clin Exp Hypertens A. 1988;10:119-133.
13. American Diabetes Association Practice Guidelines. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26:80-82.
14. American Diabetes Association Practice Guidelines. Diabetic nephropathy. Diabetes Care. 2003;26:94-98.
15. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. N Engl J Med. 2000;342:145-153.
16. Sleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:2130-2131.
17. Sica DA. Old antihypertensive agents - diuretics and beta-blockers: do we know how and in whom they reduce blood pressure? Curr Hypertens Rep. 1999;1:296-304.
18. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:443-462.